Forest Laboratories Holdings Limited Patent applications |
Patent application number | Title | Published |
20140349948 | Treatment of Chronic Constipation - The invention provides methods for treating a patient with chronic constipation by administering a therapeutically effective dose of linaclotide. | 11-27-2014 |
20140287034 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 09-25-2014 |
20140162963 | Treatment of Constipation-Predominant Irritable Bowel Syndrome - The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide. | 06-12-2014 |
20130190239 | Formulations Comprising Linaclotide - The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions. | 07-25-2013 |
20130059797 | Linaclotide for the Treatment of Chronic Constipation - The invention provides methods for treating a patient with chronic constipation by administering a therapeutically effective dose of linaclotide. | 03-07-2013 |
20130012454 | Orally Disintegrating Compositions of Linaclotide - The present invention relates to orally disintegrating or dissolving pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well to various methods and processes for the preparation and use of the compositions. | 01-10-2013 |
20120213846 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 08-23-2012 |
20120004213 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE - The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds. | 01-05-2012 |
20110245254 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES - This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a β-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a β-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed. | 10-06-2011 |
20110236439 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane - The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average T | 09-29-2011 |
20110165252 | MEMANTINE FORMULATIONS - The present invention relates to pharmaceutical compositions prepared from equant-shaped crystals of memantine, such as orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs), and to methods of treating conditions, including childhood behavioral disorders (e.g., autism) and Alzheimer's disease by administering the same. | 07-07-2011 |
20110059903 | Formulations Comprising Linaclotide - The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions. | 03-10-2011 |
20100081723 | Memantine For The Treatment Of Childhood Behavioral Disorders - The present invention provides a method for the treatment of individuals diagnosed with a childhood behavioral disorder such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) by administering an effective amount of memantine. | 04-01-2010 |
20100048726 | Memantine For The Treatment Of Mild And Mild To Moderate Alzheimer's Disease - The present invention provides a method for the treatment, prevention, or delay of progression of mild, or mild-to-moderate Alzheimer's disease, by administering an effective dose of memantine. The present invention also provides a method for preventing the decrease in glucose metabolism in the cortical and sub-cortical regions of the brain in subjects with mild, or mild-to-moderate Alzheimer's disease. | 02-25-2010 |
20100010044 | NOVEL CRYSTALLINE FORM OF 2-[4-(4-FLUORO-BENZYL)-PIPERIDINE-1-YL]-2-OXO-N-(2-OXO-2,3-DIHYDRO-BENZOX- AZOL-6-YL)-ACETAMIDE - The present invention relates to a novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described. | 01-14-2010 |
20090275597 | METHODS OF TREATING CNS DISORDERS - The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists. | 11-05-2009 |
20090264522 | METHODS OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH A LOW DOSE COMBINATION OF ESCITALOPRAM AND BUPROPION - The present invention relates to a method of treating a central nervous system disorder, such as a mood disorder (e.g., major depressive disorder) or an anxiety disorder (e.g., general anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder) with a low dose combination of escitalopram and bupropion. | 10-22-2009 |
20090239848 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE - The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds. | 09-24-2009 |
20090239810 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE - The present invention relates to piperidine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds. | 09-24-2009 |
20090221583 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE - The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds. | 09-03-2009 |
20090192315 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS - Methods for the synthesis of heterocyclic compounds including N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide and pharmaceutically acceptable salts thereof. | 07-30-2009 |
20090143593 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS - Methods for the synthesis of heterocyclic compounds including N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide and pharmaceutically acceptable salts thereof. | 06-04-2009 |
20090082326 | SOLUBLE DOSAGE FORMS CONTAINING CEPHEM DERIVATIVES SUITABLE FOR PARENTERAL ADMINISTRATION - The present invention relates to new dosage forms of cephem compounds, useful for the treatment of bacterial infections. The dosage forms are stable, exhibit enhanced solubility, and are particularly well suited for, e.g., parenteral administration. | 03-26-2009 |
20090036468 | PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS AND METHODS OF TREATMENT USING DOPAMINE RECEPTOR LIGANDS - The present invention relates to pharmaceutical compositions containing dopamine receptor ligands and selective serotonin reuptake inhibitors and to methods of treating disorders such as schizophrenia, major depressive disorder and bipolar depression using combinations of dopamine receptor ligands and selective serotonin reuptake inhibitors. The present invention also relates to methods of treating depression using dopamine receptor ligands. | 02-05-2009 |
20090030007 | NOVEL SOLVATE AND CRYSTALLINE FORMS OF CARBAMOYL-CYCLOHEXANE DERIVATIVES - The present invention relates to novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives and, more particularly, to novel solvate and crystalline forms of trans-1{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea hydrochloride. Processes for the preparation of these forms, compositions containing these forms, and methods of use thereof are also described. | 01-29-2009 |
20080300390 | REDUCING CARBOHYDRATE DERIVATIVES OF ADAMANTANE AMINES, AND SYNTHESIS AND METHODS OF USE THEREOF - The present invention relates to reducing carbohydrate derivatives of adamantane amines of Formula A or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R | 12-04-2008 |